In previous Phase I/II trials (NCT02187848), the drug achieved an objective response rate (ORR) of 20.3% (95% CI: 12.27–31.71%) in a cohort of non-squamous NSCLC patients (n = 64) with CEACAM5 expression ≥50%29. Here, CEACAM5 is linked to non-small cell lung carcinoma.